Republication : Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
BACKGROUND: Eight human catalytic phosphoinositide 3-kinase (PI3K) isoforms exist which are subdivided into three classes. While class I isoforms have been well-studied in cancer, little is known about the functions of class II PI3Ks.
MATERIALS AND METHODS: The expression pattern and functions of the class II PI3KC2β isoform were investigated in a panel of tumour samples and cell lines.
RESULTS: Overexpression of PI3KC2β was found in subsets of tumours and cell lines from acute myeloid leukemia (AML), glioblastoma multiforme (GBM), medulloblastoma (MB), neuroblastoma (NB), and small cell lung cancer (SCLC). Specific pharmacological inhibitors of PI3KC2β or RNA interference impaired proliferation of a panel of human cancer cell lines and primary cultures. Inhibition of PI3KC2β also induced apoptosis and sensitised the cancer cells to chemotherapeutic agents.
CONCLUSION: Together, these data show that PI3KC2β contributes to proliferation and survival in AML, brain tumours and neuroendocrine tumours, and may represent a novel target in these malignancies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Anticancer research - 42(2022), 6 vom: 01. Juni, Seite 3217-3230 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boller, Danielle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute leukemia |
|---|
| Anmerkungen: |
Date Completed 02.06.2022 Date Revised 03.06.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.21873/anticanres.15812 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341634395 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341634395 | ||
| 003 | DE-627 | ||
| 005 | 20231226012231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/anticanres.15812 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM341634395 | ||
| 035 | |a (NLM)35641277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boller, Danielle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Republication |b Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.06.2022 | ||
| 500 | |a Date Revised 03.06.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
| 520 | |a BACKGROUND: Eight human catalytic phosphoinositide 3-kinase (PI3K) isoforms exist which are subdivided into three classes. While class I isoforms have been well-studied in cancer, little is known about the functions of class II PI3Ks | ||
| 520 | |a MATERIALS AND METHODS: The expression pattern and functions of the class II PI3KC2β isoform were investigated in a panel of tumour samples and cell lines | ||
| 520 | |a RESULTS: Overexpression of PI3KC2β was found in subsets of tumours and cell lines from acute myeloid leukemia (AML), glioblastoma multiforme (GBM), medulloblastoma (MB), neuroblastoma (NB), and small cell lung cancer (SCLC). Specific pharmacological inhibitors of PI3KC2β or RNA interference impaired proliferation of a panel of human cancer cell lines and primary cultures. Inhibition of PI3KC2β also induced apoptosis and sensitised the cancer cells to chemotherapeutic agents | ||
| 520 | |a CONCLUSION: Together, these data show that PI3KC2β contributes to proliferation and survival in AML, brain tumours and neuroendocrine tumours, and may represent a novel target in these malignancies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PI3KC2β | |
| 650 | 4 | |a acute leukemia | |
| 650 | 4 | |a brain tumours | |
| 650 | 4 | |a cell proliferation | |
| 650 | 4 | |a migration | |
| 650 | 4 | |a neuroendocrine tumours | |
| 650 | 4 | |a pharmacological inhibition | |
| 650 | 7 | |a Isoenzymes |2 NLM | |
| 700 | 1 | |a Doepfner, Kathrin T |e verfasserin |4 aut | |
| 700 | 1 | |a Laurentiis, Angela DE |e verfasserin |4 aut | |
| 700 | 1 | |a Guerreiro, Ana S |e verfasserin |4 aut | |
| 700 | 1 | |a Marinov, Marin |e verfasserin |4 aut | |
| 700 | 1 | |a Shalaby, Tarek |e verfasserin |4 aut | |
| 700 | 1 | |a Depledge, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Robson, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Saghir, Nahid |e verfasserin |4 aut | |
| 700 | 1 | |a Hayakawa, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kaizawa, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Tomonobu |e verfasserin |4 aut | |
| 700 | 1 | |a Ohishi, Takahide |e verfasserin |4 aut | |
| 700 | 1 | |a Fattet, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Delattre, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Schweri-Olac, Anelia |e verfasserin |4 aut | |
| 700 | 1 | |a Höland, Katrin |e verfasserin |4 aut | |
| 700 | 1 | |a Grotzer, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Frei, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Spertini, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Waterfield, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Arcaro, Alexandre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anticancer research |d 1987 |g 42(2022), 6 vom: 01. Juni, Seite 3217-3230 |w (DE-627)NLM012601454 |x 1791-7530 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:6 |g day:01 |g month:06 |g pages:3217-3230 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/anticanres.15812 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 6 |b 01 |c 06 |h 3217-3230 | ||